多替拉韦妊娠安全性药物警戒数据库分析
该研究检索了WHO VigiAccess、英国MHRA、EMA EudraVigilance和FDA FAERS四个药物警戒数据库,分析整合酶抑制剂、蛋白酶抑制剂和非核苷逆转录酶抑制剂相关神经管缺陷报告。结果显示多种抗逆转录病毒药物均有神经管缺陷报告,多替拉韦相关6例,但因缺乏明确分母和重复病例难以解读。作者强调药物警戒数据库局限性大,亟需前瞻性妊娠随访和出生监测研究。
要点
- 四个药物警戒数据库均报告了多种抗逆转录病毒药物相关的神经管缺陷病例。
- 多替拉韦相关神经管缺陷共识别6例,但因缺乏明确分母难以解读。
- 药物警戒数据库存在缺乏分母和重复病例等局限,需前瞻性出生监测研究。
核心结论
- 药物警戒数据库显示多种抗逆转录病毒药物均有神经管缺陷报告,多替拉韦相关6例,但因缺乏明确分母和重复病例难以解读。
- 药物警戒数据库局限性大,亟需前瞻性妊娠随访和出生监测研究。
研究设计与样本
- 分析四个药物警戒数据库(WHO VigiAccess、英国MHRA、EMA EudraVigilance、FDA FAERS)中神经管缺陷报告。
- 检索4种整合酶抑制剂、2种蛋白酶抑制剂和2种非核苷逆转录酶抑制剂的先天性或家族性疾病报告。
主要发现
- WHO VigiAccess报告116例反应,英国MHRA报告8例,EMA EudraVigilance报告20例,FAERS报告44例神经管缺陷。
- 多替拉韦相关神经管缺陷在四个数据库中共识别6例。
- 病例因缺乏明确分母而非常难以解读。
临床怎么用
- 临床应认识到药物警戒数据库信号需谨慎解读,不能直接用于估算风险。
- 对使用抗逆转录病毒药物的孕妇应加强前瞻性随访和出生监测。
局限性
- 药物警戒数据库缺乏明确暴露患者分母。
- 存在难以识别的重复病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Botswana Tsepamo study reported neural tube defects (NTDs) in 4 of 426 (0.94%) infants of women receiving preconception dolutegravir (DTG) antiretroviral therapy (ART) vs 14 of 11 300 (0.12%) receiving preconception non-DTG ART. Data are needed to investigate this potential safety signal. Clinicians, patients, and pharmaceutical companies can report adverse drug reactions (ADRs) to pharmacovigilance databases. Data from ADRs reported to various pharmacovigilance databases were searched for NTDs. METHODS: Four pharmacovigilance databases (World Health Organization [WHO] VigiAccess; United Kingdom Medicines Health Regulatory Authority [UK MHRA]; European Medicines Agency [EMA] EudraVigilance; US Food and Drug Administration Adverse Event Reporting System [FAERS]) with online data availability were analyzed for NTD reports for 4 integrase inhibitors (DTG, raltegravir, elvitegravir, bictegravir), 2 protease inhibitors (darunavir, atazanavir), and 2 nonnucleoside reverse transcriptase inhibitors (nevirapine, efavirenz). Reports in the system organ class "congenital or familial disorders" were searched for NTDs. RESULTS: NTDs have been reported among infants born from women taking a wide range of antiretrovirals in 4 pharmacovigilance databases (WHO VigiAccess, 116 reactions; UK MHRA, 8 cases; EMA EudraVigilance, 20 cases; FAERS, 44 cases). Six NTDs were identified for DTG across the pharmacovigilance databases. Cases were very hard to interpret, given the lack of clear denominators. CONCLUSIONS: Pharmacovigilance databases have many limitations, most importantly lack of a clear denominator for patients exposed to the drug of interest and duplicate cases that are difficult to identify. Given widespread use of new antiretroviral drugs worldwide and anticipated use of new drugs, prospective follow-up of pregnant women and birth surveillance studies such as Tsepamo are critically needed.
引用
- van De Ven NS, Pozniak AL, Levi JA, et al. Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. Clin Infect Dis. 2020. PMID: 31595301. doi:10.1093/cid/ciz684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。